We have observed
7 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after
December 14, 2012).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
SEMISYNTHETIC DERIVATIVES OF NYSTATIN A1
THERAPEUTIC VACCINE FOR TREATMENT OF DIABETES TYPE 1 IN CHILDREN, APPLICATION OF THE CELL SORTER AND THE METHOD OF MULTIPLYING TREG CELLS TO PRODUCE THERAPEUTIC VACCINE FOR TREATMENT OF DIABETES TYPE 1
THE NEW DERIVATIVES OF (Z)-1,2-DIPHENYLETHENE
SOLID LIPID NANOPARTICLES OF ROXITHROMYCIN FOR HAIR LOSS OR ACNE
A METHOD OF DETECTING UROGENITAL NEOPLASMS, THE APPLICATION, AND THE SET TO DETECT THE NEOPLASTIC DISEASE OF THE UROGENITAL SYSTEM
METHODS FOR IDENTIFYING RESPONSE OF PATIENTS SUFFERING FROM PSORIASIS TO GENISTEIN TREATMENT AND MOLECULAR ASSAYS THEREFOR
AN IMMUNOGENIC VACCINE AGAINST THE HCV AND/OR HBV